RA Capital Management BCAX Position
Active7-Fund ConvergenceRA Capital Management held their position in Bicara Therapeutics Inc. (BCAX) in Q4 2025, holding $117.1M worth of shares across 6,955,993 shares.
The position was first reported in Q3 2024 and has been tracked across 6 quarterly 13F filings.
BCAX is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Ficerafusp alfa in 747 days (Apr 30, 2028), making the timing of RA Capital's position particularly relevant.
Short interest stands at 20.8% of float with 14.7 days to cover, indicating significant bearish positioning against RA Capital's long thesis.
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Full company profile →Short Interest
20.8%
14.7 days to cover
RA Capital Management BCAX Position History
Frequently Asked Questions
Does RA Capital Management own BCAX?
Yes. As of Q4 2025, RA Capital Management holds 6,955,993 shares of Bicara Therapeutics Inc. (BCAX) valued at $117.1M. This data comes from their SEC 13F filing.
How many hedge funds own BCAX?
7 specialist biotech hedge funds currently hold BCAX, including Deerfield Management, Deep Track Capital, Baker Bros. Advisors and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy BCAX?
RA Capital Management's position in BCAX was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's BCAX position increasing or decreasing?
RA Capital Management held their BCAX position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BCAXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →